HIMS was previously skirting the edge, using compounded drugs to bypass patent benefits, but the FDA clearly stated it would take decisive action against "large-scale marketing of illegal generic drugs" and directly named HIMS. With the $49 weight-loss drug taken off the shelves, what else can they sell?
This doesn't feel like a problem of cheap valuation, but rather an issue of regulators not tolerating the grey area of compounded drugs. It's okay to bet on a rebound after an oversold drop, just don't fool yourself into thinking it's a value investment trap.
$Hims & Hers Health(HIMS.US)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
